Yersinia is a gram-positive bacteria causing terminal ileitis, enterocolitis, acute diarrhea, mesenteric lymphadenitis, and sepsis. Species of Yersinia cause gastroenteritis and bubonic plague and are often observed in children, and men more than women. Moreover, the prevalence of bubonic plague and yersiniosis is reportedly high in North America, North Europe, and Scandinavian counties, therefore making these regions the largest markets for Yersinia diagnostics. Furthermore, greater adoption of novel molecular diagnostic tools and higher awareness also contribute to the dominance of these markets. On the other hand, Asia Pacific Yersinia diagnostics market holds great potential due to wide presence of untapped opportunities in the emerging Asian countries and significantly high prevalence of Yersinia infection in Japan.
Treatment of Yersinia infections includes drugs such as aminoglycosides, cephalosporins, tetracyclines, trimethoprim-sulfamethoxazole (TMP-SMZ), and fluoroquinolones. The diagnostic methods used include ELISA, tube agglutination, radioimmunoassay, ultrasonography, stool culture, CT scan and colonoscopy among others. Definite detection of Yersinia enterocolitica isolates can also be performed through sequencing of 16S rRNA gene. Immunoblot with plasmodial encoded Yersinia protein also enables serological identification. However, development of more sensitive, efficient and yet simple rapid diagnostic systems which can be applied to direct and indirect diagnosis still remains a challenge in this market.
The global Yersinia Diagnostics market is segmented on the following bases:
Key players identified for Yersinia Diagnostics market include but are not limited to:
Abbott Laboratories, Inc., Hologic, F. Hoffmann La-Roche, Becton Dickinson, Danaher Corporation, Bio-Rad Laboratories, Affymetrix, Inc., Thermo Fisher Scientific, and others.
This report offers:
